Klus Pharma to Attend ESMO Congress 2024

Klus Pharma will attend the European Society for Medical Oncology (ESMO) Congress 2024 to be held in Barcelona, Spain from September 13 to 17, 2024. As one of the most influential global oncology events hosted annually, ESMO Congress provides a prominent meeting platform for oncology researchers, clinicians, patients, and healthcare industry representatives to share, learn, and discuss the latest advances in oncology research and treatment options.

Attendees from our parent company, Kelun-Biotech, will also present recent clinical updates for anti-TROP2 ADC sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) which are summarized below.

1. Efficacy and safety of sac-TMT plus pembrolizumab (KEYTRUDA®) in patients with recurrent or metastatic cervical cancer (CC), to be presented in a mini oral session on September 15, 2024, 14:55-15:00, local time (presentation number: 716MO).

2. Safety and efficacy of sac-TMT monotherapy in patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a Phase 2 study, to be presented in a mini oral session on September 15, 2024, 14:50-14:55, local time (presentation number: 715MO).

3. Exploratory analysis of patients with or without prior PD-(L)1 inhibitors in Phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer (TNBC), to be presented as a poster on September 16, 2024, local time (presentation number: 386P).

The abstracts for the above studies were published on the official website of the ESMO Congress on September 9, 2024, local time.